Boston Scientific Corp (BSX) stock analysis
Boston Scientific Corp (BSX) clears 7 of this site's 8 mechanical value filters, 5 of 8 Buffett-style checks and 5 of 5 Lynch-style checks. At $46.01 it trades 6.7% above this site's neutral DCF value (a margin of safety of -6.7%). Its earnings quality rates Strong and it returns −0.5% to shareholders net of dilution. Figures are as of October 23, 2026, from SEC filings and market data refreshed weekly; this is educational analysis, not investment advice.
Data as of October 23, 2026. Refreshed weekly from SEC filings and market data.
What does Boston Scientific do?
Boston Scientific makes minimally invasive medical devices for heart rhythm, cardiovascular, urology and digestive conditions, such as stents, catheters, heart-rhythm and heart-valve products.
Brands and businesses it owns
- Watchman
- Farapulse
- Axonics
- Rezum
What stands out about Boston Scientific?
- The share price implies 9.6% yearly growth. At $46.01, BSX's free cash flow of $2.52 per share would have to grow 9.6% a year, fading to 2.5% by year 10, for this site's DCF (10% discount rate) to match the price. This site's baseline starts at 8%, so the price asks for more growth than the baseline. Change the assumptions.
- Misses 1 of the 8 value filters. It fails vs 200-day MA (±12%) (-20.8%); the other 7 pass. See every filter.
- The margin of safety is falling. It went from +1% on Oct 7 to -7% on Oct 23 across 5 weekly readings. See the trend.
- Insiders have been buying. 6 open-market purchases were reported in SEC Form 4 filings in the last 90 days, about $81.2 million in all. See the Insider Buying Tracker.
- Owners are being diluted. Its net shareholder yield is −0.5%: more stock is issued than is bought back or paid out. See Shareholder Yield Leaders.
How has Boston Scientific's share price moved?
The interactive price chart needs JavaScript.
Is Boston Scientific undervalued? The value diligence check
Every value-investing signal this site computes for this stock, gathered in one place: the same real numbers from the tools below, not a new score.
- Margin of safety (DCF) -6.7%
- P/E vs. its own history 18.0x · at/below its cheapest point Real range: 49.3x–95.4x over 5 years (net income per diluted share from each fiscal year's 10-K, paired with the real closing price at that fiscal year-end).
- Wall St. analyst rating Buy · 4.05/5 37 analysts this month: 10 strong buy, 19 buy, 8 hold, 0 sell, 0 strong sell (Finnhub). Down from 4.08 last month.
- Altman Z″-Score (bankruptcy risk) 2.78 · Safe zone
- Earnings quality (is the profit real?) Strong · 1 watch Beneish M-score −2.52 · accruals −4.0% of assets · 165% of profit arrived as cash · stock comp 1.5% of revenue · share count +1.1% a year. From the latest 10-K (year to Dec 2025) - see the Earnings Quality Screener for how each check is scored.
- Shareholder yield (cash back to owners) −0.5% net Latest fiscal year (2025): dividends 0.0% + buybacks 0.0% − stock comp 0.5%, as a share of today's market cap. Stock comp outruns what comes back in cash. Over 14 years its split-adjusted share count fell 2%. See Shareholder Yield Leaders.
- Capital needed to grow (See's test) $7.48 per $1 of new profit · Capital-hungry · but only 10% return on capital Operating profit $1.1B → $2.9B, capital needed $15B → $28B, 2016–2025 (3-year averages); return on capital now 10% before tax. Buffett's See's Candies needed $0.42 per $1 of new profit, FlightSafety $3.20, a typical grower about $5. See Capital-Light Compounders.
- PEG (growth at a reasonable price) 0.39 · Well under fair P/E 18.0× ÷ 46.6% a year of growth behind it. 30th lowest of 447 stocks with a usable PEG. Lynch's fair value is a PEG of 1; a very high PEG usually means almost no growth, a very low one a profit spike. See PEG Ratio Ranking.
- Compounder lenses (4) 2 of 4 · misses capital-light, cash back Capital-light growth: not cleared (only 10% return on capital); Profit is real: cleared; Cash to owners: not cleared (−0.4% a year net); Fair price (PEG): cleared. See Compounders at a Fair Price, which also lets you move the PEG bar.
- Value trap check Clear
- Munger's Inversion Check 0 flags
- Standing vs. sector peers 5 of 6 measures above the median Compared with the 33 other health care stocks this site tracks: 4 in the top third, 0 in the bottom third.
How does Boston Scientific compare with its peers?
5 of 6 measures sit above the median of the 33 other health care stocks tracked here, 4 in the top third.
- P/E ratiolower is cheaper · peer median 24.6× 18.0× ✓7th of 32
- Free-cash-flow yieldhigher is cheaper · peer median 5.5% 5.5% –18th of 34
- Return on equityhigher is better · peer median 15% 15% –17th of 34
- Net marginhigher is better · peer median 9.3% 17.5% ✓6th of 34
- Revenue growthhigher is better, year on year · peer median 8.6% 13.5% ✓9th of 34
- Debt / equitylower is safer · peer median 0.69 0.51 ✓9th of 34
Peers are the stocks this site tracks in the same sector group, not every listed competitor. The bar runs from the weakest peer (left) to the strongest (right); the tick is the middle. Measures that don't apply to a sector (cash-flow yield for banks, debt for financials) are left out.
What would Buffett & Lynch say?
Buffett's checklist is built around durable, profitable businesses bought at sensible prices, and BSX doesn't clear enough of it yet. In its favor: BSX is currently earning a strong return on shareholders' equity, carries a conservative amount of debt relative to equity, converts sales into profit at healthy margins, earns many times its interest expense, so debt service isn't a worry, and trades at a reasonable multiple of owner earnings, his own term for the real cash a business could pay out. Where it comes up short: BSX and its five-year average return on equity falls short too, so this isn't just a one-off dip, hasn't grown earnings per share fast enough over five years to impress him, and is trading above what a conservative discounted-cash-flow estimate says it's worth right now.
- ROE (TTM) > 11% ✓
- ROE (5yr avg) > 11% ✕
- Debt/Equity < 0.5 ✓
- Pretax margin > 15% ✓
- EPS growth (5yr) > 7% ✕
- Interest coverage > 5x ✓
- Trading below intrinsic value (DCF) ✕
- Price vs. owner earnings < 25x ✓
Lynch looked for growth stories that weren't overpriced for that growth, and BSX clears his bar. In its favor: BSX clears an even tighter PEG-under-1 bar he'd want for a stock growing this fast, is growing earnings 20-50% a year, his classic fast-grower zone, isn't leaning on debt to fund that growth, isn't asking too much even by a fast grower's usual richer multiple, and is generating real cash to back up a fast grower's higher price tag.
- PEG < 1 (stricter for fast growers) ✓
- EPS growth 20%-50% ✓
- Debt/Equity < 0.5 ✓
- P/E < 40 ✓
- Price/FCF < 40 ✓
- Bonus: insiders buying (90d) 6 buys, ~$81.2M
Quantitative approximations of each investor's documented approach, not endorsed by either investor or their estates - commentary, not this site's actual ranking criteria. Buffett never published a numeric checklist: only 2 of his 8 checks here trace to his own documented concepts ("owner earnings," from his 1986 shareholder letter, and "price is what you pay, value is what you get," his case against fixed P/E/P/B ceilings) - the other 6 (ROE, debt, margins, growth, interest coverage) use commonly-cited thresholds that are not numbers he himself published. The 8 hard filters below (plus the Munger check and Graham margin of safety) are this site's real, mechanical screen and are computed completely independently of the checklists above.
Berkshire Hathaway's own filing
Which of the 8 value filters does Boston Scientific pass?
- Market Cap > $25B $66.1B
- Trailing P/E < 25 17.98
- PEG Ratio < 1.5 0.39
- Price/Book < 8 2.65
- Price/Sales < 7 3.15
- EPS Growth YoY > -5% +15.3%
- vs 50-day MA (±12%) +0.8%
- vs 200-day MA (±12%) -20.8%
What is Boston Scientific's margin of safety?
+1% on 2026-10-07 → -7% on 2026-10-23 (5 weekly readings).
Where is Boston Scientific in its 52-week range?
What is the short interest in Boston Scientific?
41,410,512 shares short as of 2026-09-30 (FINRA settlement date). Reported twice a month, so this only changes roughly every two weeks, not daily.
What could go wrong with Boston Scientific? Munger's inversion check
"Invert, always invert." Instead of reasons to buy, these are reasons to hesitate, not a verdict, and not everything worth knowing about a business.
- Margin of safety, even in the bull case +37%
- Short interest under 5% of float 2.9%
- Passes most of the 6 fundamental filters 6/6 passed
- Price run-up backed by value, not just momentum +10% off 52wk low
- Debt/equity stable since 2016 0.81 → 0.47
Doesn't cover circle of competence, management quality, or accounting concerns: those need judgment, not data.
How much have Boston Scientific shareholders gained per year?
Not enough clean earnings history to compute this for BSX yet - a loss year in the window breaks the growth math rather than faking a number through it.
An earnings-based proxy, not a stock-price total return - it doesn't capture multiple expansion/contraction or reinvested dividends. EPS from BSX's own 10-K filings; dividend yield is the current trailing yield on today's price, from the same weekly fetch as the rest of this site.
What do Boston Scientific's 10-year financials show?
From BSX's own 10-K filings (SEC EDGAR): up to the last 10 fiscal years. Press any year's bars for the exact figures.
Frequently asked questions about Boston Scientific
What kind of company is Boston Scientific?
Boston Scientific makes minimally invasive medical devices for heart rhythm, cardiovascular, urology and digestive conditions, such as stents, catheters, heart-rhythm and heart-valve products. Brands and businesses it owns include Watchman, Farapulse, Axonics and Rezum. This site groups it with Health Care stocks.
Is Boston Scientific trading above or below its DCF value?
At $46.01, BSX trades 6.7% above this site's neutral DCF value of $43.11 per share, a margin of safety of −6.7%. That DCF projects free cash flow for 10 years, with growth starting at 8% and fading to 2.5%, discounted at 10%; it is one set of assumptions, not a forecast. Test your own in the Intrinsic Value Calculator.
How many of this site's 8 value filters does Boston Scientific pass?
BSX passes 7 of 8. It passes Market Cap > $25B ($66.1B), Trailing P/E < 25 (17.98), PEG Ratio < 1.5 (0.39), Price/Book < 8 (2.65), Price/Sales < 7 (3.15), EPS Growth YoY > -5% (+15.3%) and vs 50-day MA (±12%) (+0.8%). It misses vs 200-day MA (±12%) (-20.8%). The 8-filter list shows every stock that passes all of them.
Where is Boston Scientific trading compared with its 52-week range?
At $46.01, BSX trades 9.8% above its 52-week low of $41.58 and 56.2% below its 52-week high of $104.98. The Near 52-Week Low list tracks stocks in that position.
Are Boston Scientific's insiders buying its shares?
Yes: 6 open-market insider purchases of Boston Scientific shares, worth about $81.2 million in total, were reported in SEC Form 4 filings in the 90 days up to this page's last update. Only open-market purchases count here, not option exercises or stock awards. See the Insider Buying Tracker.
When does Boston Scientific report earnings next?
Boston Scientific's next earnings report is expected on October 28, 2026 before the market opens, with analysts expecting earnings of $0.74 per share. Dates come from the Finnhub earnings calendar and can move. In its last 4 quarters it beat the estimate 4 times, by an average of +2.3%.
Where do these numbers come from?
- Financial statements: Boston Scientific's 10-K annual report for the year ended Dec 31, 2025, filed Feb 17, 2026 (filing index). Every earlier year in the 10-year financials comes from the company's older 10-K filings, all listed on SEC EDGAR.
- Prices and market data: quotes, P/E and analyst ratings from Finnhub; daily price history and the 52-week range from Twelve Data, both refreshed weekly. Short interest comes from FINRA, reported twice a month.
- How to check a figure: click any number in the card above to see its exact source, and read the Editorial Standards for every rule behind the checks.
About this Boston Scientific Corp analysis
This page shows every value-investing check the site runs on Boston Scientific Corp (BSX) in one place: the 8 mechanical filters, the Buffett and Lynch checklists, a margin of safety from a disclosed DCF, earnings quality, shareholder yield and how it ranks against its sector peers. The numbers come from SEC filings and public market data, refreshed weekly, and the same rules apply to every stock on the stock list. See Editorial Standards for the sources and the rules, or run your own filters in the stock screener.